Iluvien (Fluocinolone Acetonide)

Iluvien, an ophthalmic corticosteroid, is used to manage retinal vascular disorders characterized by fluid accumulation.

• Diabetic macular edema: reduces retinal swelling and stabilizes or improves visual acuity.
• Chronic diabetic macular edema: provides sustained drug release to limit the need for repeated injections.
• Persistent macular edema unresponsive to anti‑VEGF therapy: offers an alternative anti‑inflammatory approach.

• Fluocinolone acetonide binds intracellular glucocorticoid receptors, altering gene transcription to suppress inflammatory cytokines, decrease vascular permeability, and inhibit angiogenic factors. The resulting anti‑inflammatory, immunosuppressive, and anti‑angiogenic actions lower retinal vascular leakage and edema when released from the intravitreal implant.

Iluvien may cause ocular and systemic reactions after implantation.

Common Side Effects

• Increased intraocular pressure: mild elevation requiring monitoring.
• Cataract formation: gradual lens opacity over time.
• Ocular discomfort: transient irritation or foreign‑body sensation.
• Vitreous floaters: visual disturbances from implant presence.
• Conjunctival hemorrhage: minor bleeding at insertion site.
• Blurred vision: temporary visual changes post‑procedure.

Serious or Rare Side Effects

• Endophthalmitis: severe intraocular infection requiring urgent treatment.
• Retinal detachment: separation of retinal layers, a surgical emergency.
• Persistent elevated intraocular pressure needing surgical intervention.
• Implant migration: displacement of the device within the eye.
• Severe ocular inflammation: intense uveitis or iritis.
• Optic nerve damage: rare vision‑threatening neuropathy.

Prior to Iluvien implantation, clinicians should evaluate ocular health and patient history.

• Monitor intraocular pressure: schedule regular IOP checks after insertion.
• Assess cataract progression: examine lens clarity during follow‑up visits.
• Evaluate for active ocular infection: defer implantation if infection is present.
• Use caution in glaucoma patients: heightened risk of pressure spikes.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Iluvien may interact with other ocular or systemic therapies.

Major Interactions (Avoid)

• Systemic corticosteroids: additive immunosuppression may increase infection risk.
• Intravitreal anti‑VEGF agents: combined use can heighten intraocular pressure spikes.
• Topical ocular NSAIDs: potential corneal toxicity when used concurrently.

Moderate Interactions (Monitor Closely)

• Anticoagulants: monitor for intraocular hemorrhage during and after implantation.
• Glaucoma medications: dosage adjustments may be needed if IOP rises.
• Systemic immunosuppressants: watch for signs of infection.
• Ocular antibiotics: coordinate timing to avoid interference with implant site healing.